Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01482715
What this trial is testing

Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer+1 more
pharmaand GmbH 136
Testing effectiveness (Phase 2)Looking for participantsNCT05551208
What this trial is testing

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Who this might be right for
Ovarian Cancer
Chongqing University Cancer Hospital 42
Early research (Phase 1)Study completedNCT01123876
What this trial is testing

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Who this might be right for
Gastric Cancer
AbbVie (prior sponsor, Abbott) 60
Testing effectiveness (Phase 2)Study completedNCT02890355
What this trial is testing

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage IV Pancreatic Cancer AJCC v6 and v7
National Cancer Institute (NCI) 123
Not applicableUnknownNCT04582552
What this trial is testing

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

Who this might be right for
Ovarian CancerClinical MarkerPARP Inhibitor
Xiaoxiang Chen 60
Early research (Phase 1)WithdrawnNCT06161493
What this trial is testing

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Who this might be right for
Ovarian CancerRecurrent Solid Tumors
Haider Mahdi
Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Not applicableStudy completedNCT04917744
What this trial is testing

Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

Who this might be right for
Ovarian Carcinoma
Mayo Clinic 5
Testing effectiveness (Phase 2)Looking for participantsNCT05417594
What this trial is testing

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Malignancies
AstraZeneca 695
Testing effectiveness (Phase 2)Looking for participantsNCT07460180
What this trial is testing

The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer

Who this might be right for
Ovarian CancerEpithelial CancerFallopian Tube Cancer
The Netherlands Cancer Institute 55
Early research (Phase 1)Study completedNCT00515866
What this trial is testing

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

Who this might be right for
Pancreatic Neoplasms
AstraZeneca 68
Large-scale testing (Phase 3)Study completedNCT03534453
What this trial is testing

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Who this might be right for
Relapsed Ovarian CancerFollowing Complete or Partial Response to Platinum Based ChemotherapyPlatinum Sensitive
AstraZeneca 229
Early research (Phase 1)WithdrawnNCT06719973
What this trial is testing

Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

Who this might be right for
Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
Early research (Phase 1)Study completedNCT00633269
What this trial is testing

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Who this might be right for
Neoplasm Metastasis
AstraZeneca 6
Testing effectiveness (Phase 2)Looking for participantsNCT05704621
What this trial is testing

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

Who this might be right for
Ovarian CancerDrug Related Neoplasm/Cancer
Korea University Guro Hospital 124
Not applicableLooking for participantsNCT06603506
What this trial is testing

Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

Who this might be right for
Endometrial Cancer
Centre Francois Baclesse 16
Testing effectiveness (Phase 2)Study completedNCT01540565
What this trial is testing

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierOvarian Epithelial Tumor+3 more
National Cancer Institute (NCI) 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT04550494
What this trial is testing

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate Carcinoma+28 more
National Cancer Institute (NCI) 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT06380660
What this trial is testing

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultBRCA1 MutationBRCA2 Mutation+3 more
Acerand Therapeutics (Shanghai) Limited 298
Testing effectiveness (Phase 2)Ended earlyNCT04030559
What this trial is testing

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Who this might be right for
ATM Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+14 more
University of California, Davis 11
Next Page